We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Urology

Journal Scan / Research · August 03, 2022

Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With mRCC Treated With Nivolumab Plus Ipilimumab or Cabozantinib

Clinical Genitourinary Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Genitourinary Cancer
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib
Clin Genitourin Cancer 2022 Jun 09;[EPub Ahead of Print], R Iacovelli, C Ciccarese, M Maruzzo, F Atzori, L Galli, S Scagliarini, F Massari, E Verzoni, A Cannella, MG Maratta, C Caserta, D Bimabatti, FM Deppieri, M Dessi, F Paolieri, F Riccardi, S Bracarda, U De Giorgi, U Basso, G Tortora, G Procopio

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading